AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 12 min read$LLY

Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4

Eli Lilly (LLY) reported Phase 3 ACHIEVE-4 trial results for Foundayo, showing cardiovascular safety and sustained benefits in blood sugar control and weight management for type 2 diabetes patients. Foundayo met primary safety goals, with lower cardiovascular risk compared to insulin glargine. The drug, approved for weight management, generated $98M in Q2 2026 revenue. LLY stock closed at $1,157.08, down 2.33%.

Original reporting
rttnews.com
Published Oct 1, 2026, 3:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 5:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4 — source image
Source · rttnews.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data provides a clear efficacy and safety narrative, likely prompting analysts to upgrade earnings forecasts and investors to increase exposure to LLY.

02

Market read

First‑report Phase 3 data for a high‑profile diabetes drug; material for equity traders and sector analysts.

03

What to watch

Potential regulatory scrutiny on cardiovascular claims or competitive pressure from injectable GLP‑1s could temper the rally.

Relevance 9/10Novelty 9/10Timing: today

Background

The article reports Eli Lilly's first public disclosure of Phase 3 results for Foundayo, an oral GLP‑1 agonist approved for weight management and now studied for type 2 diabetes.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly (LLY) disclosed Phase 3 ACHIEVE-4 trial results showing cardiovascular safety and significant A1C and weight benefits for its oral GLP‑1 drug Foundayo.

Expected impact

likely upward pressure as investors price in the cardiovascular safety and efficacy signals.

Evidence & confidence

Phase 3 data is a material catalyst; the trial met primary endpoints and showed mortality risk reductions, which are rare and market‑moving for a GLP‑1 therapy.

Market effects

Sector

Strengthens the oral GLP‑1 segment and may pressure competing diabetes/obesity drug makers.

Regional

U.S. biotech and pharma markets could see modest gains on the news.

Global

Highlights the growing importance of oral peptide therapeutics worldwide.

Counterpoint

What could challenge this read

If the market has already priced in the trial success, the stock may see limited upside.

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical firm reporting the trial results.

  • product
    Foundayo (orforglipron)

    Oral GLP‑1 receptor agonist under investigation for diabetes and obesity.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 1
$LLYMedAI 9/10

Eli Lilly And Company Announces Detailed Results From Phase 3 ACHIEVE-4 Trial Evaluating Foundayo Compared To Insulin Glargine

Eli Lilly's Phase 3 ACHIEVE-4 trial showed Foundayo (orforglipron) was non-inferior to insulin glargine in reducing major cardiovascular events in type 2 diabetes patients with obesity. Foundayo also improved A1C, weight, and other cardiometabolic health measures. The trial, presented at EASD and published in The Lancet, involved 2,749 participants across multiple countries.

marketscreener.com2 min
OCT 1
$LLYHighAI 8/10

Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential

Eli Lilly (LLY) reported that its antibody therapy Ebglyss met primary endpoints in a Phase 3 trial for hand-and-foot atopic dermatitis, with 53% of patients showing significant improvement. The company submitted data to the FDA for label expansion. LLY is deemed modestly undervalued with a GF Value of $1561.18, a 25.9% margin of safety, and a GF Score of 96/100. Insiders sold $3.46B in shares over the past year.

gurufocus.com2 min
SEP 30
$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

medscape.com3 min
SEP 30
$LLYHighAI 9/10

Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr

Eli Lilly (LLY) reported positive Phase 3 trial results for Foundayo, showing cardiovascular benefits in type 2 diabetes patients. The drug matched insulin glargine in preventing major adverse cardiovascular events while improving A1C levels and weight reduction. Foundayo reduced serious cardiovascular risks by 16%, cardiovascular mortality by 53%, and overall mortality by 57%.

gurufocus.com2 min